Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03089645 · ClinicalTrials.gov registry record · Phase 1
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03089645 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 39 participants.
The verdict
NCT03089645, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult subjects with advanced solid tumors.
Interventions
- BIOLOGICAL MEDI5083 monotherapy
- BIOLOGICAL MEID5083 with Durvalumab or Tremelimumab
- BIOLOGICAL Medi5083 with Durvalumab and Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-03-21 |
| Est. Completion | 2020-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03089645
The ClinicalTrials.gov registry entry for NCT03089645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MEDI5083 monotherapy is the first listed.
NCT03089645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03089645 about?
NCT03089645 is a clinical study titled "MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.". The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult subjects with advanced solid tumors.
What is the current status of trial NCT03089645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2017-03-21. Estimated completion is 2020-06-23.
What interventions are being tested in trial NCT03089645?
The interventions under investigation include: MEDI5083 monotherapy (BIOLOGICAL), MEID5083 with Durvalumab or Tremelimumab (BIOLOGICAL), Medi5083 with Durvalumab and Docetaxel (BIOLOGICAL).
Who is sponsoring clinical trial NCT03089645?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.